{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:43:54Z","timestamp":1788637434533,"version":"build-2803163510"},"reference-count":136,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.1080\/17425255.2024.2337749","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T23:09:24Z","timestamp":1711753764000},"page":"235-248","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients"],"prefix":"10.1080","volume":"20","author":[{"given":"Angela","family":"Lo","sequence":"first","affiliation":[{"name":"University of Central Florida College of Medicine, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Greenzaid","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Y.","family":"Gantz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Chodri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.209622"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_422_23"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/561018"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01655-6"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2013.35619"},{"key":"e_1_3_4_11_1","unstructured":"Memon N. Corticosteroids: drug class uses side effects drug names [Internet]. RxList; 2022. Available from: http:\/\/www.rxlist.com\/corticosteroids\/drug-class.htm"},{"key":"e_1_3_4_12_1","first-page":"7\u201310; discussio","article-title":"Topical corticosteroids: mechanisms of action","volume":"151","author":"Kragballe K","year":"1989","unstructured":"Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh). 1989;151:7\u201310; discussion 47\u201352. discussion 47-52.","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"e_1_3_4_13_1","unstructured":"Gabros S Nessel TA Zito PM Topical Corticosteroids. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 1]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532940\/"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.139874"},{"issue":"6","key":"e_1_3_4_15_1","first-page":"337","article-title":"Topical corticosteroids: choice and application","volume":"103","author":"Stacey SK","year":"2021","unstructured":"Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021;103(6):337\u2013343.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10334-018-00734-y"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.04950.x"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04449.x"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020383"},{"key":"e_1_3_4_20_1","unstructured":"Development and characterisation of clobetasol propionate loaded Squarticles as a lipid nanocarrier for treatment of plaque psoriasis - PubMed [Internet]. [cited 2024 Mar 12]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32293928\/"},{"issue":"2","key":"e_1_3_4_21_1","first-page":"135","article-title":"Choosing topical corticosteroids","volume":"79","author":"Ference JD","year":"2009","unstructured":"Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135\u2013140.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13238"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.142483"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad161"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S101233"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00587.x"},{"key":"e_1_3_4_27_1","unstructured":"Novartis. Elidel (pimecrolimus) Cream 1% [Internet]. U.S. Food and Drug Administration; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21302s005lbl.pdf."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000111510"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.1.43"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08442.x"},{"issue":"3","key":"e_1_3_4_31_1","first-page":"140","article-title":"Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis","volume":"90","author":"Tirado-S\u00e1nchez A","year":"2012","unstructured":"Tirado-S\u00e1nchez A, Ponce-Olivera RM. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Cutis. 2012;90(3):140\u2013144.","journal-title":"Cutis"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400639e"},{"key":"e_1_3_4_33_1","unstructured":"PROTOPIC\u00ae(tacrolimus) [Internet]. U.S. Food And Drug Administration; 2011 [cited 2024 Jan 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050777s018lbl.pdf"},{"key":"e_1_3_4_34_1","doi-asserted-by":"crossref","unstructured":"Goodman JJ Marbury T Clevinger S Tacrolimus prarmacokinetics in adult and psoriasis patients after topical administration of gel 0.03% 0.1% and 0.3%. MOSBY-ELSEVIER 360 PARK AVENUE SOUTH (NY) NY 10010-1710 USA; 2005. p. P196\u2013P196","DOI":"10.1016\/j.jaad.2004.10.793"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2008.07055"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.06.010"},{"issue":"4","key":"e_1_3_4_37_1","first-page":"334","article-title":"Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques","volume":"5","author":"Mart\u00edn Ezquerra G","year":"2006","unstructured":"Mart\u00edn Ezquerra G, S\u00e1nchez Rega\u00f1a M, Herrera Acosta E, et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol JDD. 2006;5(4):334\u2013336.","journal-title":"J Drugs Dermatol JDD"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550510039817"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.9.1101"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.9.1138"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb15662.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80396-9"},{"key":"e_1_3_4_43_1","unstructured":"TAZORAC\u00ae Cream [Internet]. U.S. Food and Drug Administration; 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021184s007lbl.pdf"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506040-00006"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70594-8"},{"key":"e_1_3_4_46_1","unstructured":"20600 Tazorac 0.05% and 0.1% clinical pharmacology biopharmaceutics Review(s) [Internet]. U.S. Food and Drug Administration; 1966 [cited 2024 Jan 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/20600_TAZORAC%200.05%25%20AND%200.1%25_BIOPHARMR_P1.PDF"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.108321"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.103"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.1.57"},{"issue":"12","key":"e_1_3_4_50_1","first-page":"1290","article-title":"Halobetasol and Tazarotene: further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis","volume":"17","author":"Stein Gold L","year":"2018","unstructured":"Stein Gold L, Bagel J, Lebwohl M, et al. Halobetasol and Tazarotene: further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2018;17(12):1290\u20131296.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_51_1","first-page":"4","article-title":"An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and\/or corticosteroid","volume":"66","author":"Tanghetti EA","year":"2000","unstructured":"Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and\/or corticosteroid. Cutis. 2000;66:4\u201311.","journal-title":"Cutis"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540200600201"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2020.1765180"},{"key":"e_1_3_4_54_1","first-page":"E59","article-title":"Use of Topical Tazarotene for the treatment of acne vulgaris in pregnancy: a literature review","volume":"13","author":"Han G","year":"2020","unstructured":"Han G, Wu JJ, Del Rosso JQ. Use of Topical Tazarotene for the treatment of acne vulgaris in pregnancy: a literature review. J Clin Aesthetic Dermatol. 2020;13:E59\u2013E65.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00641-4"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.037"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.439"},{"key":"e_1_3_4_59_1","unstructured":"VTAMA\u00ae (tapinarof) cream for topical use [Internet]. U.S. Food and Drug Administration; 2022 [cited 2024 Jan 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215272s000lbl.pdf."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.004"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2011.00602.x"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/10915810802244405"},{"issue":"9","key":"e_1_3_4_64_1","first-page":"37","article-title":"Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas","volume":"3","author":"Zeichner JA","year":"2010","unstructured":"Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol. 2010;3(9):37\u201340.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1984.tb00434.x"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1982.01650170033018"},{"key":"e_1_3_4_67_1","first-page":"351","article-title":"LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone","volume":"8","author":"Bagel J","year":"2009","unstructured":"Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. J Drugs Dermatol. 2009;8:351\u2013357.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1984.01650430060011"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-002-0311-5"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90323-9"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2011.06.030"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.389"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03610.x"},{"issue":"10","key":"e_1_3_4_74_1","first-page":"1997","article-title":"A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand","volume":"90","author":"Thawornchaisit P","year":"2007","unstructured":"Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai. 2007;90(10):1997\u20132002.","journal-title":"J Med Assoc Thai"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb04981.x"},{"issue":"8","key":"e_1_3_4_76_1","first-page":"868","article-title":"Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis","volume":"12","author":"Singh P","year":"2013","unstructured":"Singh P, Gupta S, Abidi A, et al. Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis. J Drugs Dermatol. 2013;12(8):868\u2013873.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"e_1_3_4_77_1","first-page":"214","article-title":"Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis","volume":"85","author":"Brouda I","year":"2010","unstructured":"Brouda I, Edison B, Van Cott A, et al. Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. Cutis. 2010;85(4):214\u2013220.","journal-title":"Cutis"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530380-000000000-00000"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310017843"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12304"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/00015550410025930"},{"key":"e_1_3_4_82_1","unstructured":"Lung BE Mowery ML Komatsu DEE. Calcitriol. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 4]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526025\/"},{"key":"e_1_3_4_83_1","unstructured":"Dovonex Product Monograph. Leo Pharma. 2021. [accessed 2024 Jan 31]. https:\/\/pdf.hres.ca\/dpd_pm\/00064010.PDF"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2018.12.006"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07561.x"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711680404"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.98.4.1397"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92157-W"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01913.x"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05228.x"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080804"},{"key":"e_1_3_4_92_1","unstructured":"Dovonex (calcipotriene) Cream 0.005% - Package Insert. 2015. [accessed 2024 Jan 31]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020273s013 020554s012lbl.pdf"},{"key":"e_1_3_4_93_1","unstructured":"Calcitriol topical (Vectical) Use During Pregnancy [Internet]. [cited 2024 Mar 9]. Available from: https:\/\/www.drugs.com\/pregnancy\/calcitriol-topical.html"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1159\/000057884"},{"key":"e_1_3_4_95_1","unstructured":"Lung BE Mowery ML Calcitriol KD. StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 12]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526025\/"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1159\/000018063"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1975.01630180068008"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.1979.18.3.228"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3030490307"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006057600400204"},{"issue":"3","key":"e_1_3_4_101_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/742241409","article-title":"Safety assessment of salicylic acid, butyloctyl salicylate, calcium salicylate, C12-15 alkyl salicylate, capryloyl salicylic acid, hexyldodecyl salicylate, isocetyl salicylate, isodecyl salicylate, magnesium salicylate, MEA-Salicylate, ethylhexyl salicylate, potassium salicylate, methyl salicylate, myristyl salicylate, sodium salicylate, TEA-Salicylate, and tridecyl salicylate","volume":"22","author":"Cosmetic Ingredient Review Expert Panel","year":"2003","unstructured":"Cosmetic Ingredient Review Expert Panel. Safety assessment of salicylic acid, butyloctyl salicylate, calcium salicylate, C12-15 alkyl salicylate, capryloyl salicylic acid, hexyldodecyl salicylate, isocetyl salicylate, isodecyl salicylate, magnesium salicylate, MEA-Salicylate, ethylhexyl salicylate, potassium salicylate, methyl salicylate, myristyl salicylate, sodium salicylate, TEA-Salicylate, and tridecyl salicylate. Int J Toxicol. 2003;22(Suppl 3):1\u2013108.","journal-title":"Int J Toxicol"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S360448"},{"issue":"3","key":"e_1_3_4_103_1","first-page":"270","article-title":"Salicylic acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis","volume":"10","author":"Kircik L","year":"2011","unstructured":"Kircik L. Salicylic acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10(3):270\u2013273.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2009.00431.x"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042728-200601000-00008"},{"issue":"2","key":"e_1_3_4_106_1","first-page":"154","article-title":"Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB","volume":"12","author":"Fetil E","year":"2002","unstructured":"Fetil E, Ozka S, Soyal MC, et al. Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB. Eur J Dermatol. 2002;12(2):154\u2013156.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.4103\/jhrr.jhrr_3_18"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04061.x"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80094-X"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.005"},{"key":"e_1_3_4_111_1","first-page":"23","article-title":"Salicylate toxicity from ingestion and continued dermal absorption","volume":"8","author":"Chin RL","year":"2007","unstructured":"Chin RL, Olson KR, Dempsey D. Salicylate toxicity from ingestion and continued dermal absorption. Calif J Emerg Med. 2007;8:23\u201325.","journal-title":"Calif J Emerg Med"},{"issue":"5","key":"e_1_3_4_112_1","first-page":"372","article-title":"Salicylic acid poisoning in dermatological therapy","volume":"151","author":"Cawley EP","year":"1953","unstructured":"Cawley EP, Wheeler CE. Salicylic acid poisoning in dermatological therapy. J Am Med Assoc. 1953;151(5):372\u2013374.","journal-title":"J Am Med Assoc"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001678"},{"key":"e_1_3_4_114_1","unstructured":"ZORYVETM (roflumilast) cream for topical use [Internet]. U.S. Food and Drug Administration; 2022 [cited 2024 Jan 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215985s000lbl.pdf"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00741-9"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxac249"},{"key":"e_1_3_4_117_1","first-page":"1","article-title":"Topical Roflumilast for Plaque Psoriasis","volume":"28","author":"O\u2019Toole A","year":"2023","unstructured":"O\u2019Toole A, Gooderham M. Topical Roflumilast for Plaque Psoriasis. Skin Ther Lett. 2023;28:1\u20134.","journal-title":"Skin Ther Lett"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14634"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5370"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000073"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.414"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.3390\/jfb14010019"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15085"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06174.x"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903085328"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05595.x"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.12.021"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11205.x"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.005"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07236.x"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-014-1485-3"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70008-8"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2020.06.009"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903268247"},{"key":"e_1_3_4_136_1","unstructured":"Pimecrolimus: Drug information [Internet]. UptoDate. [cited 2024 Jan 31]. Available from: https:\/\/medilib.ir\/uptodate\/show\/10162"},{"key":"e_1_3_4_137_1","unstructured":"TAZORAC\u00ae (tazarotene) Gel 0.05% (tazarotene) Gel 0.1% [Internet]. U.S. Food and Drug Administration; 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020600s009lbl.pdf."},{"key":"e_1_3_4_138_1","unstructured":"Coal tar: uses interactions mechanism of action | DrugBank online [Internet]. [cited 2024 Jan 31]. Available from: https:\/\/go.drugbank.com\/drugs\/DB11082"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2337749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T01:27:21Z","timestamp":1727227641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2337749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":136,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,2]]}},"alternative-id":["10.1080\/17425255.2024.2337749"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2337749","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}